CorMedix Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
CorMedix reported $355M cash on hand (Sept 30, 2026) and reaffirmed full-year 2026 revenue guidance of $325–$345M. CMS finalized the 2027 ESRD PPS rule on October 28, 2026, setting DefenCath's post-TDAPA Add-on at $8.32 per dialysis session for Q1 2027 (3.5× the current $2.37 rate). CorMedix projects the Add-on will decline in Q2 2027 but rise in Q3/Q4, with all four quarters exceeding $2.37 and an annual average above 2× the current rate, subject to CMS utilization methodology.
Why this rating
Add-on increase ($8.32 vs $2.37) is material to DefenCath revenue; represents ~39% of current market cap. Guidance reaffirmation and multi-quarter visibility into pricing uplift reduce near-term uncertainty. Strong cash position mitigates risk. Meaningful but not transformational.
Price action (we called it positive)
before filing · preread $5.50 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.